Flerie

Flerie Gross Margin

The Gross Margin of Flerie (FLERIE.ST) as of Oct 18, 2026 is -144.32 %. In the previous year, Gross Margin was -41,600.00 % — a change of -99.65% (higher).

Gross Margin

-144.32 %

YoY

-99.65%

Last updated:

Gross Margin of Flerie is 2025 -144.32 % . Gross Margin of Flerie was 2024 -41,600.00 % . It decreases by -99.65% higher compared to the previous year.

Flerie's gross margin stands at -144.3%, up from -99,672.7% several years earlier.

The Flerie Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2016
-22,589.77 SEK
Jan 1, 2017
-64,880.53 SEK
Jan 1, 2018
-64,539.06 SEK
Jan 1, 2019
-99,672.73 SEK
Jan 1, 2020
-164,940.00 SEK
Jan 1, 2023
95.74 SEK
Jan 1, 2024
-41,600.00 SEK
Jan 1, 2025
-144.32 SEK
The Flerie Gross Margin history
YEARGross MarginYoY
-144.32 %-99.65%
-41,600.00 %-43,553.01%
95.74 %-100.06%
-164,940.00 %+65.48%
-99,672.73 %+54.44%
-64,539.06 %-0.53%
-64,880.53 %+187.21%
-22,589.77 %+8,020.22%
-278.19 %-412.78%
88.94 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Flerie Stock analysis

What does Flerie do? Flerie AB, listed on the Stockholm Stock Exchange under the ticker FLERIE.ST, is a pharmaceutical company based in Solna, Sweden. The company has 6 employees and completed its initial public offering (IPO) on October 11, 2016. Flerie AB operates within the healthcare sector, specifically in the pharmaceuticals industry. The company's website is https://www.indexpharma.com/. Flerie AB is a parent company for InDex Pharmaceuticals AB and InDex Diagnostics AB. The company is engaged in the development of drugs for the treatment of diseases such as inflammation and cancer. It has a drug candidate named cobitolimod, which is intended for the treatment of ulcerative colitis. Additionally, Flerie AB develops a platform of patent-protected substances known as DNA-based ImmunoModulatory Sequences (DIMS), designed to treat various immunological diseases. The company also offers a diagnostic kit called DiBiCol, a PCR-based method that monitors seven biomarkers specific to ulcerative colitis or Crohn's disease from a single colonic biopsy. Shareholders of Flerie AB include SEB Venture Capital, Industrifonden, and NeoMed Management. The company's focus is on pharmaceutical development, with an emphasis on innovative treatments for inflammatory and immunological conditions. Flerie is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Flerie stock

Gross Margin of Flerie is -144.32 % in 2025.

Gross Margin of Flerie changed from -41,600.00 % to -144.32 %, representing a -99.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Flerie since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Flerie with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Flerie

All Key Metrics — Flerie